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To investigate the functional relationship between the matrix (MA) proteins of feline and simian immunodeficiency viruses (FIV and SIV,
respectively), we generated chimeric proviruses in which the MA-coding region of an SIV infectious molecular clone was partially or fully
replaced by its FIV counterpart. Chimeric SIV proviruses containing the amino-terminal 36 residues or the central and carboxy-terminal
regions of the FIV MA assembled into virions as efficiently as wild-type SIV. However, the resulting virions were noninfectious in single-
cycle infectivity assays. Furthermore, a chimeric SIV provirus containing the entire FIV MA was found to be severely impaired in virion
production due to inefficient membrane binding of the chimeric Gag polyprotein. Interestingly, the assembly defective phenotype of this
chimeric Gag precursor could be reversed either by introducing the G31K/G33K double amino acid substitution in the FIV-derived MA
domain or by coexpression with wild-type SIV Gag. Of note, a chimeric FIV provirus expressing the SIV MA not only assembled into
particles as efficiently as wild-type FIV, but also replicated in feline T cells with wild-type kinetics. Our results thus provide novel
information about the functional homology between the MA proteins of distantly related lentiviruses.
D 2004 Elsevier Inc. All rights reserved.
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Lentiviruses assemble their capsid shells from the viral
Gag polyprotein at the plasma membrane of the infected
cells (Clements and Wong-Staal, 1992). Concomitant with
or shortly after virus budding from the host cell, the Gag
precursor is cleaved by the virus-encoded protease into three
major structural proteins that form the mature virions:
matrix (MA), capsid (CA), and nucleocapsid (NC) (Hunter,
1994). The Gag polyprotein is by itself sufficient for the
formation of immature particles. It has been shown that
expression of Gag in different cell types, in the absence of
any other viral protein, results in the efficient formation and
release of virus-like particles (Delchambre et al., 1989;0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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protein, which corresponds to the N-terminal domain of the
Gag precursor, forms the outer shell of the core of the virus
that is directly associated with the lipid envelope (Gelder-
blom, 1991). It is well established that cotranslational
myristylation of the N-terminus of the MA domain provides
a targeting signal for Gag polyprotein transport to the
plasma membrane (Bryant and Ratner, 1990; Delchambre et
al., 1989; Go¨ttlinger et al., 1989). Moreover, for the primate
lentiviruses human and simian immunodeficiency viruses
(HIV and SIV, respectively), the association of Gag with the
plasma membrane requires, in addition to the N-myristate
group, the hydrophobic MA residues Val7 and Leu8 and a
polybasic region located between MA residues 26–32
(Gonza´lez and Affranchino, 1998; Gonza´lez et al., 1993;
Ono and Freed, 1999; Paillart and Go¨ttlinger, 1999; Yuan et
al., 1993; Zhou et al., 1994). In addition to their role in Gag
membrane binding, the HIV and SIV MA proteins
participate in particle assembly (Cannon et al., 1997; Chazal04) 157–167
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1995; Gonza´lez et al., 1996) and envelope glycoprotein
incorporation into virions (Dorfman et al., 1994; Freed and
Martin, 1996; Manrique et al., 2003; Murakami and Freed,
2000; Yu et al., 1992).
Recently, we performed a site-directed mutagenesis
analysis of the MA domain of the feline immunodeficiency
virus (FIV) Gag precursor that let us identify amino acid
regions that are necessary for efficient transport of the Gag
precursor to the plasma membrane and particle assembly
(Manrique et al., 2001). Thus, despite the little amino acid
sequence similarity between the FIV MA protein and those
of HIV-1 and SIV, the functions performed by these proteins
in virus morphogenesis appear to be analogous. In this
regard, comparison of the X-ray crystal structures of the
HIV-1 and SIV MA proteins reveals that both proteins
assemble into trimers and exhibit a high degree of structure
similarity (Hill et al., 1996; Rao et al., 1995). By contrast,
there is no structure information available for the FIV MA.
This prompted us to investigate the structural and functional
relationship between the MA proteins of primate and
nonprimate lentiviruses by analyzing the assembly pheno-
type of chimeric SIV–FIV Gag proteins in which the SIVFig. 1. Schematic representation of SIV, FIV, and chimeric Gag proteins. The w
domains corresponding to the mature Gag proteins and peptides are indicated. For S
For FIV, these are MA, CA, and NC. SIV sequences are represented by open box
chimeras are indicated above each construct by numbers referring to amino acids c
fusion points between SIV and FIV sequences are shown. The C-terminal five a
chimeras to allow proper processing at the MA-CA junction are indicated belowand FIV MA domains were exchanged. In the present study,
we show that a chimeric SIV provirus containing the FIV
MA-coding region is unable to efficiently produce viral
particles and that this defect is due to impaired membrane
association of the chimeric Gag polyprotein. By contrast,
replacement of the MA-coding region in the FIV genome
with the equivalent sequence of SIV results in a chimeric
virus that assembles into particles as efficiently as wild-type
FIV. Interestingly, this FIV chimera expressing the SIV MA
replicates in feline T cells in a wild-type manner.Results
Construction of the chimeric proviruses
To investigate the effect in Gag particle assembly of
exchanging the MA domains of two phylogenetically distant
lentiviruses, we constructed a panel of chimeric FIV–SIV
proviruses. In three of these chimeras, the MA-coding
region of SIV Gag was partially or entirely replaced with
that of FIV (Fig. 1). In the SIV(MAFIV1–36) chimera, we
substituted the N-terminal 36 residues of the FIV MA forild-type SIV and FIV Gag precursors are illustrated at the top, where the
IV, these are matrix (MA), capsid (CA), nucleocapsid (NC), p6, p2, and p1.
es and those of FIV by stippled boxes. The MA regions substituted in the
ounted from the Gag N-terminus. The three amino acids on each side of the
mino acids from the SIV or FIV MA proteins that were preserved in the
each schematic.
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point of fusion for the FIV and SIV MA sequences was
chosen to preserve the Trp–Ala motif that is conserved in
both MA proteins (see the alignment of the N-termini of the
FIV and SIV MA proteins in Fig. 4A). In the SIV(MAFIV37–
130) chimera, we maintained the SIV MA N-terminal
domain and replaced the rest of the molecule with the
equivalent region of the FIV MA. In addition, the
SIV(MAFIV1–130) chimera was constructed to substitute
the entire SIV MA region with that of FIV. It should be
pointed out that in the chimeric SIV(MAFIV37–130) and
SIV(MAFIV1–130) viruses, the C-terminal five residues of the
SIV MAwere preserved so as to allow the proper processing
of the Gag precursor at the MA-CA protease cleavage site
(Fig. 1). In the fourth construct, the FIV(MASIV1–130)
chimera, we replaced in the context of the FIV proviral
DNA almost the entire MA-coding region (amino acids 1–
130) with that of SIV without altering the FIV protease
cleavage site at the MA–CA junction (Fig. 1).
Gag expression and assembly of SIV chimeras containing
FIV MA sequences
The proviral DNAs for the wild-type SIVor the chimeric
SIV(MAFIV1–36), SIV(MAFIV37–130), and SIV(MAFIV1–130)
viruses were transfected into 293T cells and both cell and
virion lysates were analyzed by Western blotting using an
anti-SIV CA monoclonal antibody (MAb). As shown in Fig.Fig. 2. Assembly and Env glycoprotein incorporation in chimeric SIV-deriv
SIV(MAFIV37–130), and SIV(MAFIV1–130) chimeras. 293T cells were transfected
transfection, viral proteins from cell (CELLS) and virion (VIRIONS) lysates w
detected by Western blotting with an anti-SIV CA MAb. The mobilities of the Ga
standards. (B) Env glycoprotein incorporation into the assembly competent SIV chi
SIV (SIV), SIV(MAFIV1–36), or SIV(MAFIV37–130) were analyzed by Western b
panels). The mobilities of the viral TM and CA proteins are shown.2A, the chimeric SIV Gag polyproteins bearing either the N-
terminal 36 residues or the region composed of residues 37–
130 of the FIV MA assembled into virions as efficiently as
wild-type SIV Gag. In marked contrast, the chimeric SIV
Gag polyprotein containing the entire FIV MA domain was
found to be severely impaired in assembly despite being
expressed and processed in a wild-type manner (Fig. 2A).
Quantitation of the levels of CA protein in wild-type SIV
and chimeric SIV(MAFIV1–130) virion samples revealed that
the chimera produced particles with an efficiency represent-
ing 6.5 F 2.8% of the wild-type value (mean value of three
assays F SD).
Because we have previously shown that domains within
the SIV MA are necessary for the packaging of the Env
glycoprotein into virions (Gonza´lez et al., 1996; Manrique
et al., 2003), we next examined whether the assembly
competent SIV(MAFIV1–36) and SIV(MAFIV37–130) chimeric
Gag polyproteins had the ability to incorporate the SIV Env
protein. To this end, the levels of virion-associated Env were
assessed by probing virion lysates with a MAb to the
transmembrane (TM) subunit of the SIV Env glycoprotein
as we have previously described (Celma et al., 2001;
Manrique et al., 2003). Both chimeric SIV virions were
highly inefficient at recruiting the Env glycoprotein when
compared with wild-type SIV virions (Fig. 2B). Moreover,
the chimeric SIV(MAFIV1–36) and SIV(MAFIV37–130) viruses
were not capable of mediating infection in single-cycle
MAGI infectivity assays (data not shown).ed viruses. (A) Analysis of virion production by the SIV(MAFIV1–36),
with wild-type SIV (SIV) or the chimeric proviral DNAs. At 48 h post-
ere resolved by SDS-PAGE, transferred to nitrocellulose membranes, and
g and CA proteins are shown, as are the positions of the molecular weight
meras. Cell and virion lysates obtained from cells transfected with wild-type
lotting using anti-SIV TM (upper panels) and anti-SIV CA MAbs (lower
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chimeric SIV(MAFIV1–130) Gag polyprotein
As shown above, replacement of the entire MA domain
of the SIV Gag precursor with that of FIV drastically
reduces particle formation. To determine the step at which
the assembly of the SIV(MAFIV1–130) chimera is impaired,
we first examined whether this chimeric Gag polyprotein is
efficiently myristylated. To this end, cells expressing the
wild-type or chimeric SIV Gag proteins were metabolically
labeled with [35S]methionine–cysteine mix or [3H]myristic
acid. Cell lysates were assayed for SIV and FIV proteins by
immunoprecipitation and sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE) as described in
Materials and methods. As shown in Fig. 3A, lysates of
293T cells transfected with the SIV(MAFIV1–130) chimera
exhibited myristylated proteins that comigrated with the
Gag and MA proteins observed in 35S-labeled samples. The
mature MA protein derived from the chimeric SIV(MAFIV1–
130) Gag polyprotein migrated slightly faster than the wild-
type SIV MA, which is in agreement with the observed
electrophoretic mobility for the FIV MA (Manrique et al.,
2001). Indeed, the MA protein derived from the chimericFig. 3. Myristylation and subcellular localization of the chimeric SIV(MAFIV1–130
SIV(MAFIV1–130) proviral DNAs were metabolically labeled with [
35S]methionine
Cell lysates were assayed for the presence of SIV- and FIV-specific proteins by imm
mixture of sera from SIV-infected macaques and FIV-infected cats (lane SIV[MA
(B) Cell fractionation assays. Cells expressing wild-type SIV Gag, nonmyristylate
metabolically labeled with [35S]methionine–cysteine mix. Cells were mechanicall
fractions. The Gag proteins were immunoprecipitated from each fraction and subj
relative amount of Gag present in the cytosolic (S) and membrane (P) fractions pur
the chimeric SIV(MAFIV1–130) Gag protein. The radioactivity of the Gag bands wa
mean values and standard deviations of three independent experiments.SIV(MAFIV1–130) Gag comigrates with authentic FIV MA
(data not shown). Our results demonstrate that replacement
of the SIV MAwith that of FIV does not interfere with Gag
myristylation.
To assemble into particles, the SIV Gag polyprotein must
associate with the cell plasma membrane. To investigate the
ability of the chimeric SIV Gag containing the FIV MA
domain to interact in vivo with cellular membranes, we
performed cell fractionation studies. Cells expressing the
chimeric SIV(MAFIV1–130) Gag polyprotein were metabol-
ically labeled, swollen in hypotonic buffer, physically
disrupted, and fractionated into cytosolic and membrane
fractions in the presence of 0.15 M NaCl. For comparison,
we also analyzed partitioning with the cytosol and
membrane fractions of wild-type and nonmyristylated SIV
Gag proteins as well as of wild-type FIV Gag. We have
previously used a similar assay to define the membrane
association ability of SIV Gag mutants (Gonza´lez and
Affranchino, 1998). As expected, the wild-type SIVand FIV
Gag proteins were mostly localized to the membrane
fraction (Figs. 3B and C). In contrast, the majority (about
70%) of the chimeric SIV(MAFIV1–130) Gag precursor was
present in the cytosolic fraction, which is similar to the) Gag polyprotein. (A) 293T cells transfected with wild-type SIV (SIV) or
–cysteine mix or [3H]myristic acid as described in Materials and methods.
unoprecipitation with sera from SIV-infected macaques (lane SIV) or with a
FIV1–130]). The positions of the viral Gag, CA, and MA proteins are shown.
d SIV Gag, the chimeric SIV(MAFIV1–130) Gag, or wild-type FIV Gag were
y disrupted and fractionated into cytosolic (S) and membrane-enriched (P)
ected to SDS-PAGE and autoradiography. (C) Graphic representation of the
ified from cells expressing wild-type SIV Gag, nonmyristylated SIV Gag, or
s quantitated as described in Materials and methods. The data represent the
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protein (Figs. 3B and C). These results indicate that
substitution of the FIV MA domain for that of SIV reduces
the membrane binding efficiency of the chimeric Gag
precursor.
Reversion of the assembly defective phenotype of the
SIV(MAFIV1–130) chimera by the G31K/G33K MA double
amino acid substitution
Our evidence indicated at this point that the defect in
particle assembly of the chimeric SIV(MAFIV1–130) Gag
polyprotein was at the membrane targeting or association
step. In the case of HIV-1 and SIV Gag proteins, membrane
targeting and association is highly dependent on the
presence of an N-terminal cluster of basic residues in the
MA domain (Gonza´lez et al., 1993; Yuan et al., 1993; Zhou
et al., 1994). This basic region may establish electrostatic
interactions with acidic phospholipids on the cytoplasmic
face of the plasma membrane, thus providing additional
membrane binding energy to that contributed by the N-
myristate moiety (Zhou et al., 1994). Of note, the FIV MA
conserves only three of the five basic amino acids present in
the SIV MA polybasic region composed of residues 26–32
(Fig. 4A). We therefore speculated whether we could
reverse the assembly defective phenotype of the chimeric
SIV(MAFIV1–130) Gag protein by simultaneously replacing
the FIV MA glycines at positions 31 and 33 by lysines so as
to increase the positive charge of this MA region (Fig. 4A).
To this end, these MA substitutions were introduced into theFig. 4. Effect of the G31K/G33K MA double amino acid substitution on the assem
N-terminal regions of the SIV and FIV MA proteins. Identical or similar amino ac
terminus of both sequences is shown in boldface letters. The glycine-to-lysine sub
chimera are indicated. (B) 293T cells were transfected in parallel with the wild-ty
DNAs. At 48 h post-transfection, viral proteins from cell (CELLS) and virion (VI
membranes, and detected by Western blotting with an anti-SIV CA MAb.SIV(MAFIV1–130) molecular clone and the resulting DNA
construct, the SIV(MAFIV1–130)/G31K/G33K chimera, was
transfected into 293T cells. For comparison, cells were
transfected in parallel with the proviral DNAs for wild-type
SIV or the SIV(MAFIV1–130) chimera. Both cell and virion
lysates were assayed for the presence of the SIV CA protein
by Western blotting. Remarkably, introduction of the G31K/
G33K double amino acid substitution into the FIV MA
region of the SIV(MAFIV1–130) chimera resulted in a
substantial enhancement of particle production when com-
pared with the original chimera (Fig. 4B). Indeed, the levels
of SIV(MAFIV1–130)/G31K/G33K particles represent 59.2 F
4.7% of those of wild-type SIV (average of three assays F
SD). This result indicates that the assembly defective
phenotype of the SIV(MAFIV1–130) chimera can be reversed
by transforming the N-terminal basic region of the FIV MA
into an SIV MA-like polybasic domain.
Reversion of the assembly defective phenotype of the
chimeric SIV(MAFIV1–130) Gag polyprotein by coexpression
with wild-type SIV Gag
To further investigate the nature of the impairment in
assembly exhibited by the SIV Gag chimera containing the
FIV MA domain, we next asked whether wild-type SIV Gag
could rescue the chimeric Gag into extracellular particles.
We cotransfected 293T cells with the proviral DNAs for
wild-type SIV and the SIV(MAFIV1–130) chimera. As
controls, we included cells transfected with each of the
proviral DNAs. Cell and virion lysates were analyzed bybly phenotype of the chimeric SIV(MAFIV1–130) virus. (A) Alignment of the
ids are indicated with asterisks. The cluster of basic residues within the N-
stitutions that were introduced into the MA domain of the SIV(MAFIV1–130)
pe SIV (SIV), SIV(MAFIV1–130)/G31K/G33K, or SIV(MAFIV1–130) proviral
RIONS) lysates were resolved by SDS-PAGE, transferred to nitrocellulose
Fig. 5. Rescue of the chimeric SIV(MAFIV1–130) Gag polyprotein into virions by coexpression with wild-type SIV Gag. 293T cells were cotransfected with the
proviral DNAs for wild-type SIV (SIV) and SIV(MAFIV1–130). Cells transfected with wild-type SIV or the chimeric SIV(MAFIV1–130) proviral DNAs were
included as controls. Cell (CELLS) and virion (VIRIONS) lysates were analyzed by immunoblotting using either a MAb specific for the SIV MA or pooled
sera from FIV-infected cats. The positions of the Gag and MA proteins are indicated, as are those of the molecular weight standards.
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cats or a MAb to the SIV MA. This allowed us to
distinguish in the cotransfection samples between the FIV
MA derived from the chimeric Gag polyprotein and that
from wild-type SIV Gag. Analysis of the cell lysates fromFig. 6. Characterization of the chimeric FIV(MASIV1–130) provirus. (A) Assemb
parallel with the proviral DNAs for Petaluma FIV-14 (FIV) or the FIV(MASIV1–13
immunoblotting with an anti-FIV CA MAb. (B) Replication kinetics of the ch
transfection of CrFK cells were normalized for RT activity and used to infect MY
intervals postinfection. Mock, mock-infected cells.the cotransfection experiments showed that both the wild-
type and chimeric Gag proteins were efficiently expressed
and processed into the corresponding mature MA products
(Fig. 5, CELLS). Interestingly, coexpression of the chimeric
SIV(MAFIV1–130) Gag protein with wild-type SIV Gagly phenotype of the chimeric virus. Feline CrFK cells were transfected in
0) chimera. Cell (CELLS) and virion (VIRIONS) lysates were analyzed by
imeric FIV(MASIV1–130) virus in feline T cells. Virus stocks obtained by
A-1 cells. Virus replication was assessed by measuring RT activity at 3-day
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associated FIV MA with respect to that released from cells
expressing only the chimera (Fig. 5, VIRIONS). These
results indicate that the chimeric SIV(MAFIV1–130) Gag
protein can be rescued into virions by coexpression with
wild-type Gag, which implies that the Gag chimera retains
the ability to establish Gag–Gag molecular interactions.
Gag expression, assembly, and infectivity of a chimeric FIV
provirus harboring the SIV MA domain
To further examine the functional relationship between
the SIV and FIV MA proteins, we constructed a chimeric
FIV provirus in which the MA domain of Gag was replaced
with that of SIVand analyzed whether the resulting chimeric
Gag protein was capable of directing virion assembly in
feline cells. Crandell feline kidney (CrFK) cells were
transfected in parallel with the wild-type FIVor the chimeric
FIV(MASIV1–130) proviral DNAs and the resulting cell and
virion lysates were analyzed by Western blotting with a
MAb to the FIV CA protein. The chimeric FIV(MASIV1–130)
Gag polyprotein exhibited expression and processing
patterns similar to those of wild-type FIV Gag (Fig. 6A,
CELLS). Interestingly, this chimeric Gag protein produced
virions as efficiently as wild-type FIV Gag (Fig. 6A,
VIRIONS), which demonstrates that particle formation in
feline cells can be driven by a chimeric FIV Gag polyprotein
containing the SIV MA domain.
Wenext examined the ability of the chimeric FIV(MASIV1–
130) to replicate in the T lymphoid MYA-1 cell line. Virus
replication was monitored over time by measuring reverse
transcriptase (RT) levels in cell-free culture supernatants. As
shown in Fig. 6B, the chimeric FIV(MASIV1–130) virus
replicated in MYA-1 cells with wild-type kinetics. Taken
together, these results indicate that substitution of the SIVMA
for that of FIVresults in an assembly competent and infectious
chimeric virus.Discussion
To investigate the functional homology between the
MA proteins of two distantly related lentiviruses, we
generated chimeric proviruses derived from SIV and FIV.
In three of these chimeras, the MA-coding region of the
SIV gag gene was partially or completely replaced with
the equivalent regions of FIV. The chimeric SIV(MAFIV1–
36) and SIV(MAFIV37–130) viruses assembled into virions as
efficiently as wild-type SIV. In contrast, the chimeric SIV
containing the entire FIV MA domain was highly
inefficient at producing extracellular particles. The assem-
bly defective phenotype of the chimeric SIV(MAFIV1–130)
virus was due to an impairment in the ability of the Gag
precursor to associate with the plasma membrane as
evidenced by its preferential distribution in the soluble
fraction obtained in cell fractionation assays. Indeed,despite being efficiently myristylated, the chimeric SIV
(MAFIV1–130) Gag polyprotein exhibited a membrane-
binding capacity resembling that of nonmyristylated SIV
Gag. Interestingly, the inability of the SIV(MAFIV1–130)
Gag chimera to form extracellular particles could be
reversed by the MA double amino acid substitution
G31K/G33K, which generates at the N-terminus of the
chimeric Gag polyprotein a polybasic region similar to that
of the SIV MA. Moreover, the chimeric SIV(MAFIV1–130)
Gag protein could be rescued into virions by coexpression
with wild-type SIV Gag, indicating that the chimeric Gag
protein is able to oligomerize with wild-type Gag. Taken
together, these results demonstrate that the assembly
defective phenotype of the SIV(MAFIV1–130) chimera can
be reversed by providing a membrane-binding competent
domain either in cis, by the G31K/G33K MA mutation, or
in trans, by coexpression with wild-type SIV Gag.
Our data demonstrating that the chimeric SIV(MAFIV1–
130) Gag polyprotein can be recruited into particles by
wild-type SIV Gag are in line with a previous report in
HIV-1 that showed that coexpression with wild-type Gag
could reverse the assembly defective phenotype of MA
mutants impaired in plasma membrane targeting (Ono et
al., 2000). Therefore, our results, together with those of
Ono et al. (2000), suggest that a certain degree of Gag
oligomerization occurs previous to Gag transport to the
plasma membrane. In support of this view, it has been
shown that virus assembly intermediates are formed in the
cytoplasm of HIV-1-infected cells (Lee and Yu, 1998).
In marked contrast to the assembly defective phenotype of
the SIV(MAFIV1–130) chimera, the chimeric SIV(MAFIV1–36)
and SIV(MAFIV37–130) viruses produced extracellular par-
ticles as efficiently as wild-type SIV. The fact that the
SIV(MAFIV37–130) chimera is assembly competent demon-
strates that the central and carboxyl regions of the FIV MA
are functionally compatible with the interactions between
Gag molecules that drive virion formation. The assembly
phenotype of the SIV(MAFIV1–36) chimera, which contains
the FIV MA N-terminus in the context of the SIV Gag
precursor, is particularly interesting. It may seem paradoxical
that fusing the FIV MA N-terminus to the central and C-
terminal regions of the SIV MA allows proper Gag
membrane association and particle assembly whereas the
presence of the entire FIVMA in the SIV Gag precursor does
not. A possible explanation is that in the case of the chimeric
SIV(MAFIV1–36) Gag molecule, a membrane-binding com-
petent domain may be generated between the FIV MA N-
terminus and sequences within the SIV MA regions
preserved in the chimera. The X-ray structure of the SIV
MA reveals that the C-terminal loop connecting a-helices H6
and H7 lies near the N-terminal polybasic region (Rao et al.,
1995). Based on this spatial arrangement, it is conceivable
that the basic SIV MA residues within this loop (Lys93,
Lys95, and His96) may contribute to the membrane-binding
activity of the N-terminal cluster of basic amino acids. The
concept that basic residues at the MA C-terminus participate
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for the HIV-1 MA that exhibits a similar structure to that of
SIV (Hill et al., 1996; Massiah et al., 1994).
To further define the relationship between the roles
played by the MA proteins of FIV and SIV, we constructed
the chimeric FIV(MASIV1–130) provirus that contains the
SIV MA in place of that of FIV. Interestingly, not only did
this chimera assemble into virions in feline cells as
efficiently as wild-type FIV, but it also displayed wild-type
replication kinetics in feline T cells. Therefore, the SIV MA
domain is able to perform the functions played by FIV MA
in the virus life cycle.
The phenotype of the FIV(MASIV1–130) virus, which is
assembly competent and infectious, contrasts with that
observed for other chimeric retroviruses. Indeed, substitu-
tion of the HIV-1 MA for the murine leukemia virus
(MuLV) MA resulted in a chimeric virus that replicated in
murine cells at a reduced rate when compared to wild-type
MuLV (Deminie and Emerman, 1994). This chimeric virus
assembled inefficiently because of improper intracellular
targeting of the chimeric Gag precursor (Deminie and
Emerman, 1994). Moreover, a chimeric HIV-1 provirus
containing the MuLV MA domain could efficiently
produce extracellular particles in transfected murine
fibroblasts yet failed to replicate in these cells and was
poorly infectious in human cells (Reed et al., 2002).
In summary, our results demonstrate that the SIV MA
can functionally replace the FIV MA whereas the latter in
place of the SIV MA does not allow efficient SIV assembly.
Partial replacements in the SIV MAwith equivalent regions
of its FIV counterpart result in assembly competent viruses;
however, these chimeras are noninfectious. The data
presented in this study provide insight into the roles played
by the domains shared by the Gag proteins of primate and
nonprimate lentiviruses.Materials and methods
Cell lines
293T, CrFK, and MAGI-CCR5 (HeLa-CD4-CCR5/LTR-
h-gal) cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (FBS,
GIBCO). MAGI-CCR5 cells were additionally maintained in
medium containing 0.2 mg/ml G418 (geneticin), 0.1 mg/ml
hygromycin B, and 1 Ag/ml puromycin. The feline T
lymphoblastoid MYA-1 cell line (Miyazawa et al., 1989)
was maintained in RPMI medium supplemented with 10%
FBS, 100 U/ml interleukin-2 (Roche), and 50 AM h-
mercaptoethanol.
Construction of chimeric and mutant proviral DNAs
Proviral constructs were based on the SIVSMMPBj1.9
(Dewhurst et al., 1990) and the Petaluma FIV-14 (Olmstedet al., 1989) infectious molecular clones. Chimeric proviral
DNAs were generated by a PCR-based strategy using the
Elongase enzyme high-fidelity PCR mix (Invitrogen). The
sequences of primers and the details of the cloning
strategies are available upon request. To generate the
SIV(MAFIV1–130) chimera in which the MA domain of SIV
was replaced by that of FIV, the amplified fragment
corresponding to the SIV long terminal repeat (LTR) region
(nucleotides [nt] 1–828) was ligated to the FIV region
encoding the first 130 amino acids of MA (nt 628–1017).
The resulting fragment was in turn ligated to a PCR-
amplified fragment encoding the last five amino acids of the
SIV MA and the first 41 amino acids of the SIV CA (nt
1219–1356). For the construction of the SIV(MAFIV1–36)
chimera that harbors the first 36 codons of the FIV MA in
the context of the SIV genome, the SIV LTR region was
linked to a fragment coding for the first FIV MA 36
residues (nt 628–735) and then ligated to the fragment
corresponding to the SIV MA residues 36–135 and the
first 41 amino acids of the SIV CA (nt 934–1356). To
generate the SIV(MAFIV37–130) chimera, a 933-bp fragment
corresponding to the LTR and the first 35 codons of
PBj1.9 MA was ligated to a fragment coding for the FIV
MA residues 37–130 (nt 736–1017). The resulting frag-
ment was then ligated to the fragment comprising the last
five codons of the SIV MA and the first 41 codons of the
SIV CA region. The three chimeric fragments were
digested with SalI–AfeI and substituted for the correspond-
ing wild-type region in the parental PBj1.9 DNA construct.
The FIV(MASIV1–130) chimera, in which the SIV MA-
coding region was substituted for that of FIV in the context
of the FIV-14 genome, was generated by ligating the
following PCR-amplified fragments: a 627-bp fragment
containing the FIV-14 LTR, a fragment coding for the first
SIV MA 130 residues (PBj nt 829–1218), and an FIV-14
fragment encoding the last five residues of the MA, the
entire CA, and part of the NC (nt 1018–1880). The
resulting chimeric fragment was digested with EcoRI and
then ligated into the similarly digested FIV-14 proviral
DNA. The chimeric constructs were initially screened by
restriction mapping and then by DNA sequencing to
confirm that the DNA fragments were linked in the
appropriate reading frame. An SIV proviral DNA encoding
a nonmyristylated form of the Gag polyprotein was
generated as previously described (Gonza´lez et al., 1993).
Introduction of the MA double amino acid substitution
G31K/G33K into the chimeric SIV(MAFIV1–130) proviral
DNA was performed on the 1.4-kb SalI–AfeI fragment of
this construct by asymmetric PCR-based site-directed
mutagenesis as we have previously described (Manrique
et al., 2001).
Transfections
293T or CrFK cells (grown in 60-mm diameter dishes)
were transfected with 10 Ag of the proviral DNAs by using
M.L. Manrique et al. / Virology 329 (2004) 157–167 165Lipofectamine 2000 (Invitrogen) and harvested 48 h post-
transfection. For the cotransfection experiments in 293T
cells, the wild-type SIVSMM PBj1.9 and the chimeric
SIV(MAFIV1–130) proviral DNAs were transfected at a
DNA ratio of 1:1.
Viral protein analysis and Western blotting
Transfected 293T or CrFK cells were washed twice with
ice-cold phosphate-buffered saline (PBS) and lysed at 4 8C
in lysis buffer (50 mM Tris–HCl [pH 8.0], 150 mM NaCl,
1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate,
1 mM phenylmethylsulfonyl fluoride [PMSF], and 10 Ag/
ml aprotinin). The culture supernatants from the trans-
fected cells were filtered through 0.45-Am-pore-size
syringe filters and virions were pelleted from the clarified
supernatants by ultracentrifugation (100000  g, 90 min,
4 8C) through a 20% (wt/v) sucrose cushion. Cell- and
virion-associated proteins were resolved on a SDS–10%
polyacrylamide gel, blotted onto nitrocellulose membranes,
and analyzed by Western blotting coupled with an
enhanced chemiluminescence assay (ECL, Amersham
Biosciences) as previously described (Celma et al., 2001;
Manrique et al., 2001). For the quantitative analysis of
virion-associated proteins, Western blots were developed
with ECL plus reagent (Amersham Biosciences) and the
resulting chemifluorescent signal was analyzed as previ-
ously described (Manrique et al., 2003). FIV Gag-related
proteins were detected by using the anti-FIV CA MAb
PAK3-2C1 obtained through the NIH AIDS Research and
Reference Reagent Program. The MAb KK60 used to
detect the SIV Gag and CA proteins as well as the anti-
SIV TM MAb KK41 were obtained from J. Stott and K.
Kent through the MRC AIDS Directed Program. Horse-
radish peroxidase-conjugated anti-mouse immunoglobulin
(Amersham Biosciences) was used as secondary antibody.
In the case of the cotransfection of 293T cells with the
wild-type SIVSMM PBj1.9 and the chimeric SIV(MAFIV1–
130) proviral DNAs, cell and virion lysates were immuno-
blotted with either a MAb specific for the SIV MA (KK59;
NIH AIDS Research and Reference Reagent Program)
followed by peroxidase-conjugated anti-mouse immuno-
globulin, or pooled sera from FIV-infected cats and
subsequent incubation with horseradish peroxidase-conju-
gated protein A (Amersham Biosciences).
Metabolic labeling and cell fractionation studies
293T cells transfected with wild-type SIVSMM PBj1.9 or
the chimeric SIV(MAFIV1–130) proviral DNA were meta-
bolically labeled 48 h post-transfection. After starvation in
cysteine- and methionine-deficient medium for 1 h at 37 8C,
the cells were labeled in deficient medium containing 250
ACi/ml of [35S]methionine–cysteine mix (N1000 Ci/mmol,
EXPRE35S35S Protein Labeling Mix; NEN) for 4–6 h
as previously described (Gonza´lez and Affranchino, 1998).For [3H]myristic acid labeling, transfected cells were
incubated in complete medium containing 150 ACi/ml
[9,10-3H(N)]myristic acid (60 Ci/mmol; NEN) for 6–8 h.
Metabolically labeled cells were washed with cold PBS and
lysed in lysis buffer. Lysates were spun at 16000  g for 2
min and the postnuclear supernatants were subjected to
immunoprecipitation with serum from SIV-infected mac-
aques alone or mixed with anti-FIV serum. Immunopreci-
pitated viral proteins were separated by SDS-PAGE and
visualized by autoradiography of the dried gels as pre-
viously described (Gonza´lez and Affranchino, 1998; Man-
rique et al., 2001). Cell fractionation assays were performed
essentially as we have described before (Gonza´lez and
Affranchino, 1998). Briefly, metabolically 35S-labeled cells
were mechanically disrupted in hypotonic buffer (20 mM
Tris–HCl [pH 7.5], 10 mM KCl, 1 mM EDTA, 1 mM
PMSF, 10 Ag/ml aprotinin) and fractionated by differential
centrifugation into a 1000  g pellet (nuclei and unbroken
cells), a 100000  g pellet (P100), and supernatant (S100).
The supernatants were concentrated by ultrafiltration in
Centricon-10 microconcentrators (Amicon Inc.). The con-
centrated samples were adjusted to 1 lysis buffer. Equal
portions of P100 and S100 fractions were assayed for SIV
and FIV proteins by immunoprecipitation and analyzed by
SDS-PAGE as described above. The amount of labeled Gag
precursor in each fraction was quantitated by Phosphor-
Imager analysis using the ImageQuant software (Molecular
Dynamics).
RT assays
Quantitation of virion-associated RT in cell-free culture
supernatants from transfected or infected cells was
performed by using a nonisotopic RT assay kit (Roche
Diagnostics) essentially as previously described (Manrique
et al., 2003). RT levels were calculated relative to the
recombinant HIV-1 RT enzyme provided in the kit.
Infectivity in MAGI or T cell lines
Wild-type and chimeric SIV proviral constructs were
transfected into 293T cells for virus production as described
above. At 48 h post-transfection, the supernatants were
filtered, normalized for RT activity, and used to infect
MAGI-CCR5 cells as we have previously described (Celma
et al., 2001; Manrique et al., 2003). At 2 days post-
infection, cells were fixed and stained with X-Gal (5-
bromo-4-chloro-3-indolyl-h-d-galactopyranoside). Relative
infectivity was determined as previously described (Celma
et al., 2001; Manrique et al., 2003). To obtain replication
kinetics data in the feline T cell line MYA-1, we first
generated virus stocks by transfection of CrFK cells as
described above. Equal RT activity in volume-adjusted
supernatants was added to 2  105 MYA-1 cells and
allowed to adsorb for 4 h. The cells were washed twice
with PBS to remove residual virus and incubated with fresh
M.L. Manrique et al. / Virology 329 (2004) 157–167166medium. Cell cultures were split at a 1:2 ratio every 3 days
with fresh medium and aliquots of culture supernatants
were frozen at 80 8C for RT determination at the
conclusion of the experiment.Acknowledgments
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